New hope for HIV patients with stubborn hepatitis c
NCT ID NCT00221650
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tested a combination of two drugs, peginterferon alfa-2a and ribavirin, as a second-line treatment for chronic hepatitis C in 17 people with HIV who did not respond to their first hepatitis C treatment. The goal was to see if this 48-week treatment could make the hepatitis C virus undetectable in the blood. The study focused on safety and effectiveness in this specific group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATITIS C, CHRONIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Pellegrin, Federation des Maladies Infectieuses, Pr RAGNAUD
Bordeaux, 33076, France
Conditions
Explore the condition pages connected to this study.